阿司匹林、肝素及其他干预措施在胎儿生长受限预防和治疗中的作用
胎儿生长受限与子痫前期等胎盘病理相关,常因螺旋动脉重塑不足导致胎盘缺血。阿司匹林可适度降低高危孕妇小于胎龄儿风险(RR 0.90,95%CI 0.81-1.00),推荐剂量≥100 mg并于16周前开始。低分子肝素预防证据不一致,Meta分析未显示对胎盘介导并发症有预防效果,应限于研究场景。
要点
- 阿司匹林可适度降低高危孕妇小于胎龄儿风险(RR 0.90,95%CI 0.81-1.00),推荐剂量≥100 mg且于16周前开始。
- 低分子肝素预防胎儿生长受限的随机对照试验证据不一致,Meta分析未显示对胎盘介导并发症复合结局有预防效果。
- 确诊胎儿生长受限后治疗选择有限,高风险时唯一管理方案为医源性早产,产时使用硫酸镁神经保护和皮质激素促胎肺成熟。
核心结论
- 阿司匹林可适度降低高危孕妇小于胎龄儿风险(RR 0.90,95%CI 0.81-1.00),推荐剂量≥100 mg并于16周前开始。
- 低分子肝素预防胎儿生长受限的随机对照试验证据不一致,Meta分析未显示对胎盘介导并发症复合结局有预防效果,应限于研究场景。
- 确诊胎儿生长受限后治疗选择有限,高风险时唯一管理方案为医源性早产,产时使用硫酸镁神经保护和皮质激素促胎肺成熟。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 阿司匹林Meta分析显示可适度降低高危孕妇小于胎龄儿风险(RR 0.90,95%CI 0.81-1.00)。
- 低分子肝素Meta分析未显示对胎盘介导并发症复合结局有预防效果(18% vs 18%;绝对风险差0.6%;95%CI 10.4-9.2)。
- 体外和体内研究提示低分子肝素可能预防胎儿生长受限,但随机对照试验证据不一致。
- 西地那非等磷酸二酯酶5抑制剂正在广泛研究,Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction随机对照试验 consortium 结果备受期待。
- 母体血管内皮生长因子基因治疗正在通过doEs Vascular endothelial growth factor gene therapy safEly impRove outcome in seveRe Early-onset fetal growth reSTriction consortium转化为临床。
关键数值与推荐
- 阿司匹林推荐剂量≥100 mg,并于16周前开始,用于预防胎儿生长受限。
- 低分子肝素预防胎儿生长受限应限于研究场景。
临床怎么用
- 高危孕妇可使用阿司匹林≥100 mg于16周前开始预防小于胎龄儿。
- 低分子肝素不推荐用于常规预防胎儿生长受限,应限于研究场景。
- 确诊胎儿生长受限且缺氧、酸中毒和宫内死亡风险高时,唯一管理方案为医源性早产,产时使用硫酸镁神经保护和皮质激素促胎肺成熟。
局限性
- 许多干预措施以子痫前期预防和/或治疗为中心,胎儿生长受限和小于胎龄儿常作为次要结局,使研究结果对确定临床意义可靠性降低。
- 低分子肝素预防胎儿生长受限的随机对照试验证据不一致。
- 人妊娠数据、尤其胎儿生长受限妊娠的数据仍非常有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fetal growth restriction and related placental pathologies such as preeclampsia, stillbirth, and placental abruption are believed to arise in early pregnancy when inadequate remodeling of the maternal spiral arteries leads to persistent high-resistance and low-flow uteroplacental circulation. The consequent placental ischaemia, reperfusion injury, and oxidative stress are associated with an imbalance in angiogenic/antiangiogenic factors. Many interventions have centered on the prevention and/or treatment of preeclampsia with results pertaining to fetal growth restriction and small-for-gestational-age pregnancy often included as secondary outcomes because of the common pathophysiology. This renders the study findings less reliable for determining clinical significance. For the prevention of fetal growth restriction, a recent large-study level meta-analysis and individual patient data meta-analysis confirm that aspirin modestly reduces small-for-gestational-age pregnancy in women at high risk (relative risk, 0.90, 95% confidence interval, 0.81-1.00) and that a dose of ≥100 mg should be recommended and to start at or before 16 weeks of gestation. These findings support national clinical practice guidelines. In vitro and in vivo studies suggest that low-molecular-weight heparin may prevent fetal growth restriction; however, evidence from randomized control trials is inconsistent. A meta-analysis of multicenter trial data does not demonstrate any positive preventative effect of low-molecular-weight heparin on a primary composite outcome of placenta-mediated complications including fetal growth restriction (18% vs 18%; absolute risk difference, 0.6%; 95% confidence interval, 10.4-9.2); use of low-molecular-weight heparin for the prevention of fetal growth restriction should remain in the research setting. There are even fewer treatment options once fetal growth restriction is diagnosed. At present the only management option if the risk of hypoxia, acidosis, and intrauterine death is high is iatrogenic preterm birth, with the use of peripartum maternal administration of magnesium sulphate for neuroprotection and corticosteroids for fetal lung maturity, to prevent adverse neonatal outcomes. The pipeline of potential therapies use different strategies, many aiming to increase fetal growth by improving poor placentation and uterine blood flow. Phosphodiesterase type 5 inhibitors that potentiate nitric oxide availability such as sildenafil citrate have been extensively researched both in preclinical and clinical studies; results from the Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction consortium of randomized control clinical trials are keenly awaited. Targeting the uteroplacental circulation with novel therapeutics is another approach, the most advanced being maternal vascular endothelial growth factor gene therapy, which is being translated into the clinic via the doEs Vascular endothelial growth factor gene therapy safEly impRove outcome in seveRe Early-onset fetal growth reSTriction consortium. Other targeting approaches include nanoparticles and microRNAs to deliver drugs locally to the uterine arterial endothelium or trophoblast. In vitro and in vivo studies and animal models have demonstrated effects of nitric oxide donors, dietary nitrate, hydrogen sulphide donors, statins, and proton pump inhibitors on maternal blood pressure, uteroplacental resistance indices, and angiogenic/antiangiogenic factors. Data from human pregnancies and, in particular, pregnancies with fetal growth restriction remain very limited. Early research into melatonin, creatine, and N-acetyl cysteine supplementation in pregnancy suggests they may have potential as neuro- and cardioprotective agents in fetal growth restriction.
引用
- Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2017. PMID: 29229321. doi:10.1016/j.ajog.2017.11.565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。